MonTa Biosciences
PrivateLast Round
Early Funding
Oct 20, 2022
Total Funding Raised
$16.99M
Company Overview
MonTa Biosciences operates in Healthcare & Life Sciences and is based in Denmark. Its latest recorded funding round was an Early Funding round in October 2022.
MonTa Biosciences is a biotechnology company that develops cancer immunotherapies using micelle-based nanoparticle technology to stimulate immune responses against tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MonTa Biosciences Comparables
Compare MonTa Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Seven and Eight Biopharmaceuticals Inc. | 83% | |
| Ascendis Pharma A/S | 74% | |
| Nektar Therapeutics | 71% |
For institutional investors. Book with your work email.
MonTa Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Oct 20, 2022 | ||||
| Series A | Jan 9, 2020 | ||||
| Accelerator | Mar 10, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 2, 2026
Monthly visitors grew 385% MoM, reaching 1.4K.
- Mar 1, 2026
Monthly visitors increased 179% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 20, 2026
MonTa Biosciences ApS, a spin-out from DTU, is developing cancer treatments that activate the body's immune system and currently tests its treatment in melanoma patients.
For institutional investors. Book with your work email.
MonTa Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MonTa Biosciences's valuation, stock price, and market status.
Is MonTa Biosciences a public or private company?
MonTa Biosciences is a private company.
What is the current stock price of MonTa Biosciences?
MonTa Biosciences is a private company, so its shares have no public market price. Caplight tracks MonTa Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MonTa Biosciences worth (valuation)?
Valuation information for MonTa Biosciences is not publicly available.
Can I buy MonTa Biosciences stock?
MonTa Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MonTa Biosciences's last funding round?
MonTa Biosciences's most recent funding round was Early Funding on October 20, 2022.
Who are the main investors in MonTa Biosciences?
Investor information for MonTa Biosciences is not publicly disclosed.
Will MonTa Biosciences IPO soon?
No public IPO plans have been announced for MonTa Biosciences.
How can I track MonTa Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in MonTa Biosciences's shares on secondary markets.